Keeping clinical trials moving during the COVID-19 pandemic

The COVID-19 crisis has upended so many aspects of conducting business in virtually all industries. The pharma and biotech world are among those dramatically impacted – particularly given the life and death nature of what they do. How can clinical trials continue to take place, when confronted with so many pandemic-related obstacles?

Since the onset of this healthcare crisis, QuickSTAT has been working closely with its pharma and biotech clients, offering contingency plans that help ensure their global clinical trials may continue. These plans, along with QuickSTAT’s life science logistics experts, have been helping companies adhere to trial protocols, keep patients safe, and ensuring they receive their therapies on time.

So, during these unprecedented times, how do clinical trial providers overcome government regulations, severely reduced airline schedules and dire economic situations? QuickSTAT offers a variety of ways to help keep your clinical trials moving. Our Direct-To-Patient Services are a viable way to keep clinical trials running as planned, with safe and reliable patient solutions during the COVID-19 pandemic.

QuickSTAT’s experts can partner with you and implement these options:

• Direct-To-Patient Services (DTP)
  Safe and reliable delivery of patient therapies direct to patients' homes, avoiding potentially dangerous trips for patients to clinics or hospitals.
• Transitioning Traditional Clinical Trials to Direct-to-Patient Services
  QuickSTAT will design new supply chain logistics plans and procedures to transition to the DTP model. We will ensure clinical trial continuity, timely deliveries and patient specimen pick up for transport directly to labs.
• Expediting Placement of Conditioned Packaging
  Strategic placement of conditioned packaging throughout a geographic region to ensure therapies are delivered on time to patients whose therapies are running low.
• Assisting with COVID-19 Research Logistics
  QuickSTAT can transport antibody specimens from patients who have recovered from coronavirus, or ship potential treatments from most places in the world, as a possible therapy for COVID-19 patients.

What's more, QuickSTAT will utilize every possible resource to meet your deadlines - including Air Charters, On-board Couriers, Next Flight Out, Direct Drives and Priority Airfreight - along with leveraging the vast network and service options of our parent company, Kuehne+Nagel.

We are here for you – throughout these challenging times and beyond. Please reach out and let QuickSTAT help you design a comprehensive logistics program to keep your clinical trials and research moving. And to stay up-to-date on COVID-19 news, Quick FAQs and links to helpful resources, please visit our coronavirus information center.